NasdaqGS:XERSPharmaceuticals
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues
Why Xeris Biopharma Holdings Stock Is Back in Focus
Xeris Biopharma Holdings (XERS) is drawing fresh attention after its 6 August 2026 update, which paired tighter full year revenue guidance with second quarter results, as well as key balance sheet and pipeline developments.
See our latest analysis for Xeris Biopharma Holdings.
The recent earnings update and tighter 2026 revenue guidance have arrived after a period of strong momentum for Xeris Biopharma Holdings. The latest share price is...